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Introduction: It is unclear whether high-dose influenza 
vaccine (HD) is more effective at reducing mortality 
among seniors. Aim: This study aimed to evaluate the 
relative vaccine effectiveness (rVE) of HD. Methods: 
We linked electronic medical record databases in the 
Veterans Health Administration (VHA) and Medicare 
administrative files to examine the rVE of HD vs stand-
ard-dose influenza vaccines (SD) in preventing influ-
enza/pneumonia-associated and cardiorespiratory 
mortality among VHA-enrolled veterans 65 years or 
older during the 2012/13, 2013/14 and 2014/15 influ-
enza seasons. A multivariable Cox proportional haz-
ards model was performed on matched recipients of 
HD vs SD, based on vaccination time, location, age, 
sex, ethnicity and VHA priority level. Results: Among 
569,552 person-seasons of observation, 207,574 
(36%) were HD recipients and 361,978 (64%) were SD 
recipients, predominantly male (99%) and white (82%). 
Pooling findings from all three seasons, the adjusted 
rVE estimate of HD vs SD during the high influenza 
periods was 42% (95% confidence interval (CI): 24–59) 
against influenza/pneumonia-associated mortality 
and 27% (95% CI: 23–32) against cardiorespiratory 
mortality. Residual confounding was evident in both 
early and late influenza periods despite matching and 
multivariable adjustment. Excluding individuals with 
high 1-year predicted mortality at baseline reduced 
the residual confounding and yielded rVE of 36% (95% 
CI: 10–62) and 25% (95% CI: 12–38) against influ-
enza/pneumonia-associated and cardiorespiratory 
mortality, respectively. These were confirmed by 
results from two-stage residual inclusion estimations.
Discussion: The HD was associated with a lower risk 
of influenza/pneumonia-associated and cardiorespira-
tory death in men during the high influenza period.
Introduction
Seasonal influenza epidemics result in substantial 
health burden. Among the 9 million veterans under 
the care of the United States (US) Veterans Health 
Administration (VHA), nearly 3,800 are estimated to 
die annually from respiratory and circulatory compli-
cations associated with seasonal influenza infections 
[1-4]. The clinical risk for hospitalisation and death is 
highest among persons aged 65 years or older (here-
inafter referred to as seniors) because of frailty and 
immunosenescence [5,6]. In 2009, the US Food and 
Drug Administration licensed an injectable high-dose 
inactivated trivalent influenza vaccine (HD) (Fluzone 
High-Dose, Sanofi Pasteur, Swiftwater, US). The HD 
contains four times more influenza haemagglutinin 
antigen than standard-dose influenza vaccines (SD) 
(60 μg vs 15 μg per strain) and is designed to provide 
improved protection in seniors.
Beginning with the 2010/11 season, the VHA began to 
introduce the HD across its medical centres, largely 
relying on individual facilities to decide the volume 
to order and on physicians to decide the recipients of 
the specific type of vaccine. While the majority of VHA 
senior patients still receive SD, the proportion of HD 
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recipients has been steadily rising, from 3% during 
2010/11 to ca 11% during 2014/15 (data not shown). 
Senior VHA patients can also obtain influenza vac-
cination using non-VHA insurance coverage, such as 
that provided by Centers for Medicare and Medicaid 
Services (Medicare), once they become eligible.
Clinical trials have shown that HD was 7% (95% confi-
dence interval (CI): 0.5–12.8) and 8% (95% CI: 0.3–14) 
more effective than SD in preventing all-cause hospital 
admissions in ambulatory and nursing home seniors, 
respectively [7,8]. The advantage of HD in preventing 
hospitalisations has also been confirmed by several 
observational studies [9-13]. However, it is unclear 
whether HD is more effective at reducing mortality 
among seniors, especially given the ongoing debate 
surrounding the scale of mortality attributable to influ-
enza and the effectiveness of influenza vaccines among 
the elderly. Although a number of HD studies have 
reported mortality outcomes [7-10], only one study has 
investigated this question as a primary objective: Shay 
et al. found that HD vaccination was 24% (95% CI: 6–42) 
more effective in preventing mortality after influenza 
hospital admission [12]. Nevertheless, potential con-
founding because of indication associated with ‘frailty’ 
bias remains to be examined and mitigated [14,15]. We 
examined the relative vaccine effectiveness (rVE) of HD 
compared with SD against mortality outcomes among 
VHA veterans during the 2012/13, 2013/14 and 2014/15 
influenza seasons.
Methods
Design and data sources
The VHA is the single largest integrated healthcare sys-
tem in the US and provides clinical care to more than 
9 million military veterans at more than 170 medical 
centres and ca 1,400 community-based outpatient clin-
ics. We obtained de-identified VHA electronic medical 
records (EMR) data and administrative health records 
for VHA enrolees from Medicare fee-for-service files. 
These records supplement the VHA database as many 
VHA patients seek healthcare outside the VHA system 
once they turn 65 and qualify for such additional ben-
efits. We obtained vital status from the VHA vital sta-
tus files and death certificate data from the National 
Death Index (NDI) through the Centre of Excellence for 
Suicide Prevention Joint Department of Veterans Affairs 
and Department of Defence Suicide Data Repository – 
NDI (extracted: 22 January 2019) [16].
Using these data sources, a retrospective cohort study 
was conducted to compare the risk of mortality among 
HD and SD recipients for the 2012/13, 2013/14 and 
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2014/15 seasons. Two causes of death were examined: 
(i) influenza- or pneumonia-associated and (ii) cardi-
orespiratory, as these were likely to be impacted by 
influenza vaccination [10]. Causes of death were classi-
fied using the International Classification of Diseases, 
10th revision (ICD-10) [17].
Ethical statement
This study was approved by the Veteran’s Institutional 
Review Board of Northern New England at the White 
River Junction VHA Medical Center (No. 903343). All 
study procedures were carried out in compliance 
with federal and institutional ethical guidelines. The 
requirement to obtain informed consent from study 
participants was waived as there was no more than a 
minimal risk to the privacy of individuals.
Study population and influenza vaccination
The study population included all VHA enrolees who 
turned 66 years or older by 1 July for each of the influ-
enza seasons and maintained their enrolment until the 
end of the season (30 June of the following year) or 
until death, whichever occurred earlier. Influenza vac-
cination was identified using current procedural termi-
nology (CPT) codes (SD CPT codes: 90655–90659 and 
Q2034-Q2039; HD CPT code: 90662). We included vet-
erans who received either an HD or SD and excluded 
any who did not have a record of vaccination or received 
more than one influenza vaccine in the same season to 
ensure valid comparison.
Influenza activity periods
For each Centers for Disease Control and Prevention 
(CDC) multi-state reporting region [18], we divided each 
season into three periods of potential influenza activ-
ity, following methods employed in previous research 
[19]. We used weekly reports of the percentage of posi-
tive influenza tests among all influenza tests performed 
in each region to define (i)  high influenza period  as 
the time between the first and last occurrences of 
2 consecutive weeks with at least 10% influenza 
positivity, (ii)  early influenza period  as the time from 
1 September to the start of the high influenza period 
and (iii)  late influenza period  as time from the end of 
the high influenza period to the end of June (Figure 1).
Baseline characteristics
For each study subject, the baseline period began at 
the end of each previous season in week 27 (begin-
ning of July) and ended at his/her influenza vaccination 
date. Characteristics measured during the baseline 
period included demographics, comorbidities, and 
healthcare utilisation. Demographics comprised age, 
sex, ethnicity, geographic region and priority rating of 
VHA care (as a proxy for socioeconomic status because 
it is partially based on income and the capacity for 
gainful employment) [20].
Comorbidities were defined according to an adaptation 
of Deyo-Charlson comorbidity score [21] using diag-
nosis codes captured during hospital and ambulatory 
visits. As a proxy measure for frailty, we used the care 
assessment need (CAN) score developed specifically 
to predict hospitalisation within 1 year among VHA 
patients. In addition to incorporating the medical con-
ditions used in the Charlson and Elixhauser scores 
[22], CAN includes sociodemographic characteristics, 
the prior year’s levels of healthcare utilisation (e.g. 
number of primary care, non-emergency department 
outpatient visits), medication use and laboratory test 
results [23]. We used the maximum CAN score in the 
4 weeks before vaccination. Healthcare utilisation was 
measured as the number of all-cause hospitalisations.
Matching
Each HD recipient was matched to at least one, and 
at most two, residents of the same VHA facility who 
received an SD within the same week. This process 
addressed temporal and geographical factors possibly 
associated with access to HD and influenza exposure 
(i.e. influenza outbreak activity). In addition, these HD 
and SD recipients were matched on all demographic 
variables including age group (65–74, 75–84 and ≥ 85 
years), sex, ethnicity (white vs other) and VHA priority 
rating (high vs low). All analyses were performed on 
the matched populations.
Statistical analysis
We used standardised mean difference (SMD) as a 
measure of statistical differences between two groups. 
SMD was calculated by dividing the difference in mean 
outcome between groups by the pooled standard 
deviation of the two groups. The absolute value of this 
division is then multiplied by 100, with a value greater 
than 10 denoting statistical significance [24]. Cox pro-
portional hazards modelling was used to estimate 
the hazard ratios (HR) and 95% CI for the association 
between receipt of the HD and mortality separately 
for each outcome and influenza activity period. Within 
each influenza period, follow-up time began on the 
index date, defined as 2 weeks following vaccination, 
or the beginning of each influenza period, whichever 
came last. This was done because in primed healthy 
adults, the peak serum antibody levels are typically 
observed 2 weeks post-vaccination [25]. We excluded 
study subjects who received vaccination within 15 days 
of the end of each influenza period to allow for at least 
1 day of follow-up. The observation period ended on 
the date of disenrollment from either VHA or Medicare, 
end of each of the three influenza season periods or 
date of death, whichever occurred first. For example, 
if a patient was vaccinated on 1 October, then his/her 
follow-up time for the early influenza period began on 
15 October. If he/she died from an influenza/pneumo-
nia-associated cause on 1 December, his/her follow-up 
time would end then, regardless of whether the high 
influenza period in his/her region had begun. The mod-
els adjusted for all baseline comorbidities and health-




Baseline characteristics after matching by standard dose vs high-dose influenza vaccination among predominantly male, 
white, senior veterans , United States, 2012/13–2014/15 (n = 569,552)
Season 2012/13 2013/14 2014/15






Study population 89,700 49,950 117,518 65,267 154,760 92,357
Sex
Female 1% 1% 1 1% 1% 1 1% 1% 1
Male 99% 99% 0 99% 99% 1 99% 99% 1
Ethnicity
White 80% 79% 3 82% 81% 2 83% 83% 2
African-American 8% 10% 4 8% 7% 3 8% 7% 3
Hispanic 8% 8% 1 7% 8% 6 6% 7% 5
Other 2% 2% 1 2% 2% 1 2% 2% 1
Unknown 1% 1% 0 1% 1% 0 1% 1% 0
Age group 
(years)
65–74 37% 38% 2 40% 41% 2 44% 45% 1
75–84 43% 42% 2 40% 40% 1 37% 37% 1
≥ 85 20% 20% 1 20% 19% 1 19% 19% 1
Priority
High priority 38% 39% 1 40% 40% 0 42% 42% 1
Low priority 62% 61% 1 60% 60% 0 58% 58% 1
HHS region
1 5% 4% 2 6% 5% 1 8% 7% 2
2 9% 9% 2 9% 9% 1 12% 11% 2
3 11% 11% 2 11% 11% 1 11% 13% 6
4 28% 28% 0 30% 30% 1 28% 27% 2
5 14% 11% 8 12% 10% 5 11% 10% 5
6 9% 11% 4 9% 10% 1 7% 7% 0
7 11% 14% 9 9% 12% 9 8% 10% 8
8 3% 3% 1 3% 3% 1 4% 3% 2
9 7% 7% 2 9% 8% 1 10% 10% 0
10 3% 3% 0 2% 2% 1 2% 2% 2
Morbidity
Malignancy 16% 18% 5 16% 18% 7 16% 18% 6
Metastatic solid tumour 1% 1% 0 1% 1% 0 1% 1% 1
Congestive heart failure 12% 12% 2 11% 12% 2 11% 12% 1
Chronic pulmonary disease 19% 20% 3 19% 20% 5 19% 20% 2
Cerebrovascular disease 10% 11% 3 9% 10% 3 9% 10% 3
Dementia 2% 2% 0 2% 2% 1 2% 2% 0
Diabetes with complications 10% 11% 3 10% 11% 3 11% 12% 3
Diabetes without chronic 
complications 39% 39% 1 39% 39% 1 39% 39% 0
HIV/AIDS 0.2% 0.2% 1 0.2% 0.2% 0 0% 0% 1
Mild liver disease 1% 1% 0 2% 2% 0 2% 2% 1
Moderate/severe liver disease 0.2% 0.2% 0 0.2% 0.2% 1 0% 0% 0
Myocardial infarction 3% 3% 0 3% 3% 2 3% 3% 1
Hemiplegia/paraplegia 1% 1% 0 1% 1% 1 1% 1% 1
Peptic ulcer disease 1% 1% 1 1% 1% 1 1% 1% 1
Peripheral vascular disease 13% 14% 4 12% 14% 5 12% 14% 6
Rheumatoid disease 2% 2% 2 2% 2% 2 2% 2% 2
Renal disease 13% 13% 0 13% 13% 2 13% 13% 1
Continuous 
variablesb
Age 74.5 74.9 5 76.9 77.1 1 76.6 76.7 2
Number of hospitalisations 0.19 0.18 2 0.13 0.11 3 0.14 0.12 5
VHA care assessment need 
score 0.05 0.04 3 0.054 0.047 9 0.05 0.04 9
HD: high-dose influenza vaccine; HHS: Health and Human Services; VHA: Veterans Health Administration; SD: standard-dose influenza 
vaccine; SMD: standardised mean difference.
a An SMD less than 10 in absolute value suggests no important difference between the two cohorts [24].
b Continuous variables reported as mean.
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We also conducted analyses with mortality as a binary 
outcome. This was achieved using a two-stage resid-
ual inclusion model, also known as control functions 
approach [26], to account for potential confounding 
from measured and unmeasured variables. The rVE 
was calculated as (1−HR) × 100%. All tests were two-
tailed, and 0.05 was the level of statistical significance. 
We performed statistical analyses using Stata 15 
(StataCorp, College Station, TX).
To further quantify the presence of confounding by 
indication due to frailty, we used a logistic regression 
model to predict mortality for all cohort members dur-
ing each influenza season. We then re-ran the fully 
adjusted Cox proportional hazard model on the sub-
population that excluded individuals at higher levels 
of illness severity, as measured by predicted one-
year mortality [19]. We estimated rVE for each season 
separately, and then pooled the results after statisti-
cally examining heterogeneity caused by inter-season 
variability.
Results
We included 569,552 person-seasons of observation 
where 207,574 (36%) were among HD recipients and 
361,978 (64%) were among SD recipients during the 
three seasons; 99% were male and 80% were of non-
Hispanic white origin (Table 1). We matched 49,950, 
65,267 and 92,357 HD recipients to 89,700, 117,518 
and 154,760 SD recipients for the 2012/13, 2013/14 
and 2014/15 season, respectively. Matched HD or SD 
recipients were similar with respect to baseline covari-
ates as well as CAN score. For the matched cohorts, we 
observed 127, 145 and 250 influenza/pneumonia-asso-
ciated deaths and 2,715, 3,379 and 4,812 cardiores-
piratory deaths for the 2012/13, 2013/14 and 2014/15 
season, respectively (Figure 2). 
During the high influenza periods, rVE ((1−HR) × 100%) 
for influenza/pneumonia-associated mortality was 
23% (95% CI: −83 to 67), 32% (95% CI: −17 to 60) and 
47% (95% CI: 21–65) for seasons 2012/13, 2013/14 and 
2014/15, respectively, with a pooled rVE of 42% (95% 
Figure 2
Hazard ratios pooled over three influenza seasons and number of deaths by cause and influenza period, among 



















































All subjects Subjects with high predicted mortality excluded Two-stage model
Season    
2012/13  13  90  24  249  1,761  705  
2013/14  12  101  32  383  2,149  847  
2014/15  21  165  64  435  2,976  1,401  
Total  46  356  120  1,067  6,886  2,953  
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CI: 24–59), presented in Table 2. For cardiorespiratory 
deaths, the rVE were 23% (95% CI: 13–32), 28% (95% 
CI: 19–35), and 30% (95% CI: 23–36) for the three 
study seasons, respectively, with a pooled rVE of 27% 
(95% CI: 23–32).
During the early influenza periods, rVE (1−HR) for influ-
enza/pneumonia-associated mortality was 0% (95% 
CI: −56 to 32), 10% (95% CI: −88 to 57) and 23% (95% 
CI: −5 to 43) for seasons 2012/13, 2013/14 and 2014/15, 
respectively, with a pooled rVE of 17% (95% CI: −3 to 
37). For cardiorespiratory deaths, rVE was 5% (95% CI: 
−41 to 37), 7% (95% CI: −8 to 20) and 14% (95% CI: 
8–20) for the three study seasons, respectively, with a 
pooled rVE of 13% (95% CI: 7–18).
During the late influenza periods, rVE (1−HR) for influ-
enza/pneumonia-associated mortality was 4% (95% 
CI: −143 to 62), 13% (95% CI: −86% to 59%) and 16% 
(95% CI: −46 to 52) for seasons 2012/13, 2013/14 and 
2014/15, respectively, with a pooled rVE of 13% (95% 
CI: −22 to 48). For cardiorespiratory deaths, rVE was 
3% (95% CI: −39 to 32), 9% (95% CI: −5 to 22) and 13% 
(95% CI: 2–22) for the three study seasons, respec-
tively, with a pooled rVE of 11% (95% CI: 3–19).
One-year mortality was accurately predicted 
(C-statistic = 0.84) using a logistic regression model. 
Excluding individuals with greater than 5% predicted 
mortality (ca 21% of the cohort) had a considerable 
impact on the HR estimates (Figure 2). During the early 
influenza periods, pooled rVE for influenza/pneumonia-
associated mortality was 1% (95% CI: −44 to 46) and 
2% (95% CI: −28 to 32) for cardiorespiratory deaths, 
noticeably closer to no effect (i.e. rVE = 0%) compared 
with the analysis including all cohort members (Table 
2). The estimates for the late influenza periods also 
moved closer to the null when individuals at high pre-
dicted probabilities of mortality were excluded; pooled 
rVE were −4% (95% CI: −98 to 89) and 1% (95% CI: −12 
to 15) for influenza/pneumonia-associated and car-
diorespiratory mortality, respectively. Excluding indi-
viduals with high 1-year predicted mortality at baseline 
reduced the residual confounding and yielded rVE of 
36% (95% CI: 10–62) and 25% (95% CI: 12–38) against 
influenza/pneumonia-associated mortality and cardi-
orespiratory mortality, respectively, during the high 
influenza period.
Confounding by indication was further studied with a 
two-stage residual inclusion model. Pooling findings 
from all three seasons, the adjusted rVE estimate of 
HD vs SD during the high influenza periods was 23% 
(95% CI: 17–28) against influenza/pneumonia-associ-
ated mortality and 30% (95% CI: 23–38) against cardi-
orespiratory mortality (Table 3). The estimates differed 
by season, but with overlapping CI. This was more 
evident for influenza/pneumonia-associated mortal-
ity: the rVE was 29% (95% CI: 21–36), 11% (95% CI: −1 
to 22) and 21% (95% CI: 11–30) for the three seasons, 
respectively. Finally, we estimated adjusted rVE during 
the baseline (summer) period against all-cause hospi-
talisations to assess confounding by indication. The 
rVE during the baseline period were close to the null: 
−7% (95% CI: −21–5), −6% (95% CI: −11 to −2) and 5% 
(95% CI: 2–8) for the three seasons, respectively, for a 
pooled estimate of −1% (95% CI: −5–2) (Table 3).
Discussion
In our analysis of the 2012/13, 2013/14 and 2014/15 
influenza seasons, we found receiving HD among a 
population of predominantly male, white, senior vet-
erans to be associated with an additional reduction 
in mortality as compared with receiving SD. Although 
only a portion of all winter deaths can be attributed 
to influenza [27], the additional 36% (95% CI: 10–62) 
reduction in influenza/pneumonia-associated mortal-
ity and 25% (95% CI: 12–38) reduction in cardiorespira-
tory mortality for HD vs SD present substantial impact 
as nearly 3,800 VHA patients die annually from res-
piratory and circulatory complications associated with 
seasonal influenza infections [1].
An HR of 1 implies a null effect (i.e. no difference in vac-
cine effectiveness). Thus, we expected to see HR fur-
thest from the null, indicating largest relative vaccine 
effect, for the periods when influenza is in high circula-
tion and more likely to trigger the largest proportion of 
deaths. For all seasons, and for both influenza/pneu-
monia-associated and cardiorespiratory mortality, we 
observed the same pattern: The HR were the furthest 
from the null during the high influenza period, while 
HR were much closer to the null during the early and 
late influenza periods. This created a U-shape pattern, 
suggesting statistically significant rVE during the high 
activity periods. During the early and late influenza 
periods, most rVE estimates associated with either car-
diorespiratory or influenza/pneumonia-associated mor-
tality displayed evidence of differential impact outside 
the high activity periods, albeit smaller. For example, 
the rVE for cardiorespiratory mortality were both statis-
tically significant for the 2014/15 season, 14% (95% CI: 
8–20) in the early period and 13% (95% CI: 2–22) in the 
late period, if not controlled for residual confounding. 
During the early and late influenza periods, when influ-
enza viruses were not circulating or circulating at a low 
level, these significant rVE could indicate the presence 
of residual confounding after matching and multivaria-
ble survival analysis. The appearance and confirmation 
of residual confounding during these periods are not 
new. Campitelli et al., among others, have found simi-
lar bias in their study of influenza vaccines’ impact on 
mortality [19]. However, this bias cannot explain away 
all the observed mortality benefit associated with HD 
during the high influenza periods, as the magnitudes 
of the rVE for the early and late influenza periods were 
half to one third of the rVE during the high influenza 
period. Furthermore, excluding individuals with high 
1-year predicted mortality at baseline resulted in rVE 
much closer to the null, indicating reduced levels of 
residual confounding. Receipt of SD was more preva-
lent than HD among veterans with high 1-year predicted 
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mortality (Supplementary Table 1), which impacted the 
estimate of rVE. Before this exclusion, the average 
1-year predicted mortality for HD and SD recipients was 
3.3% and 4.2%, respectively, with a not statistically 
significant SMD of 9. This suggests a successful bal-
ance by matching of this surrogate measure of frailty. 
Nevertheless, the exclusion approach appeared to 
have a larger impact than matching, which could sug-
gest that HD conferred better protection relative to SD 
for the frailest veterans. Finally, it was reassuring that 
almost no residual confounding was observed during 
the non-influenza circulation period (summer) against 
all-cause hospitalisations.
The relative effectiveness between HD and SD was 
estimated during three seasons with varying circulating 
strains and vaccine efficacy. While influenza A(H3N2) 
viruses predominated in both the 2012/13 [28] and 
2014/15 [29] seasons, 2013/14 [30] was the first influ-
enza A(H1N1)pdm09–predominant season since 2009. 
Nevertheless, VE were similar for both the 2012/13 
(49%; 95 CI: 43–55) and 2013/14 season (52%; 95 CI: 
44–59) but dramatically lower for the 2014/15 sea-
son, at an overall effectiveness of 19% (95 CI: 10–27) 
[31]. The combination of low VE and predominant 
influenza A(H3N2) viruses, which are associated with 
higher rates of influenza-associated hospitalisations 
among the elderly, may have contributed to the highest 
recorded rate of laboratory-confirmed, influenza-asso-
ciated hospitalisations in the US, at 319.2 per 100,000 
population in the 2014/15 season. This rate exceeded 
the previously highest record of 183.2 per 100,000 
for the 2012/13 season by 74% [29]. Given the vary-
ing rVE, VE and circulating viruses, it would be inter-
esting to examine the association among the three. 
Unfortunately, including these variables in the model 
would add greater complexity and require additional 
seasons and data. Moreover, some veterans’ vaccina-
tions were not recorded in the VHA or CMS databases, 
resulting in incomplete vaccination data. We believe 
this incompleteness, and resulting misclassification, 
could have had a substantial impact on the estimation 
of VE. To evaluate the VE of each vaccine or to study 
the impact of repeated vaccinations would also require 
significant undertaking to avoid misclassifying those 
without vaccination records as being not vaccinated. To 
convey clear public health messages, we believe these 
should be studied carefully in the future.
Table 2
Relative vaccine effectiveness of high-dose vs standard dose influenza vaccination and mortality by influenza period, 
matched and adjusted using Cox proportional hazards model, among predominantly male, white, senior veterans, United 
States, 2012/13–2014/15 (n = 569,552)
Population Season
Influenza/pneumonia cause of death Cardiorespiratory cause of death
Influenza period
Early High Late Early High Late
































































































































































CI: confidence interval; rVE: relative vaccine effectiveness.
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Our comparative effectiveness analysis of HD and 
SD vaccination on mortality explores the same ques-
tion over the same period as Shay et al.’s analysis, 
but with differences in study populations, healthcare 
providers, outcome definitions and statistical meth-
ods. Nevertheless, our results were consistent with 
their overall rVE: 24% (95% CI: 6–42) in post-influenza 
deaths, defined as “a death occurring in the 30 days 
following a Medicare claim for an inpatient hospitali-
sation or an emergency department visit with a diag-
nosis of influenza.” [12] Clinical trial data have shown 
that the VE of HD might be greater for A(H3N2) than for 
A(H1N1) influenza viruses [9]. This could explain some 
variation by season in our study, as our rVE were 29% 
(95% CI: 21–36) for 2012/13 (predominantly A(H3N2)), 
11% (95% CI: −1 to 22) for 2013/14 (predominantly 
A(H1N1)pdm09) and 21% (95% CI: 11–30) for 2014/15 
season (predominantly A(H3N2)). The pattern was 
similar, although less drastic than observed by Shay 
et al.: 36.4% (95% CI: 9.0–56) for 2012/13 and 2.5% 
(95% CI: −47 to 35) for 2013/14 season. We focused on 
the high influenza period while Shay et al. analysed 
vaccinations that occurred mostly in what we catego-
rised as the early and high influenza periods. However, 
they defined the period by the proportion of positive 
tests ≥ 75th percentile for each region/season, which 
is similar to the 10% positive test rate that we used. 
Shay et al’s primary method of adjusting for potential 
confounding, in addition to restricting participation to 
beneficiaries who were vaccinated in pharmacies, was 
multivariable adjustment, but they did not conduct 
matching or additional statistical modelling.
Strengths
The appropriate analysis and estimation of rVE depends 
on the correct adjustment for confounding by indication 
where some of the confounders are unmeasured. In our 
studies, we attempted three different approaches: (i) 
the previous event rate ratio method, a type of differ-
ence-in-differences analysis [14], (ii) the instrumental 
variable method, an econometric technique [15] and 
(iii) the current approach where findings of a vaccine 
effect during early and late influenza periods could 
indicate the presence of residual confounding after 
matching and multivariable analysis. Each approach 
has strengths and weaknesses that could be amplified 
or ameliorated with specific study populations, data-
bases or influenza seasons examined. In this study, we 
experimented with different methods (e.g. two-stage 
residual inclusion estimation model) and cut-offs (e.g. 
high 1-year mortality risk) that sometimes resulted in 
divergent point estimates or wide CI, which could be 
due to varying sample sizes and statistical assump-
tions. As we continue to improve on our approaches, 
we hope that a pattern will emerge from this body of 
work that could contribute to the scientific inquiry of 
the rVE of HD and SD.
Moreover, we analysed more than half a million vacci-
nations and almost 10 thousand deaths. The large sam-
ple allowed us to adjust for more confounding variables 
without compromising statistical power, although not 
calculated beforehand. We combined data from VHA 
EMR records and Medicare administrative claims to 
compile a complete picture of healthcare encounters 
experienced by our study population. We studied both 
influenza/pneumonia and cardiorespiratory mortality, 
using the CDC’s gold standard causes-of-death data 
[32]. We matched on the location and time of vaccina-
tion to better account for temporal and geographical 
factors associated with influenza disease movement. 
In addition, we matched on age group, sex, ethnicity 
and VHA priority rating. This comprehensive matching 
has been shown to improve the accuracy of estimation, 
although we would have constructed finer age groups 
if we had a larger sample size [33].
Limitations
The CDC’s causes-of-death data lacks standardisation 
[32]. Since influenza and pneumonia are comparatively 
rare as causes of death, their designation might be 
more subjective especially during periods of low influ-
enza activity. Thus, under-diagnosing could lead to var-
iation in assignments of underlying cause of death. The 
VHA has a unique population: it is more than 90% male, 
predominantly white, and tends to have greater disease 
burden than the general US population, thus our find-
ing is not generalisable [34]. Despite combining EMR 
records from the VHA and administrative claims from 
Medicare, a small amount of data might still be missing 
for those enrolled in Medicare Advantage (MA) plans. 
The proportion that enrolled in MA after vaccination 
Table 3 
Relative vaccine effectiveness of high-dose vs standard dose influenza vaccination and mortality during high influenza 
period, matched and adjusted using two-stage residual inclusion model, among predominantly male, white, senior veterans, 
United States, 2012/13–2014/15 (n = 569,552)
Season
Influenza/pneumonia cause of death Cardiorespiratory cause of death All-cause hospitalisations (baseline)
rVE % (95% CI) rVE % (95% CI) rVE % (95% CI)
2012/13 29 (21 to 36) 26 (2 to 44) −7 (−21 to 5)
2013/14 11 (−1 to 22) 29 (27 to 30) −6 (−11 to −2)
2014/15 21 (11 to 30) 31 (30 to 32) 5 (2 to 8)
Pooled 23 (17 to 28) 30 (23 to 38) −1 (−5 to 2)
CI: confidence interval; rVE: relative vaccine effectiveness.
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was small (2.5%), and since the most important data 
to the study were their vaccination status (HD vs SD), 
mortality outcome and baseline characteristics, the 
amount of missing data was negligible in the context 
of our study. Ninety-nine per cent of the vaccines we 
studied were egg-based with a 1:2 ratio between triva-
lent HD and trivalent SD in our matched samples. Two-
thirds of the trivalent SD were supplied by the same 
company. Although rVE might differ depending on the 
specific types of SD (e.g. cell-based, adjuvanted, etc.), 
we did not have the needed sample size to study the 
impact of different vaccine types. Additional data on 
morbidities such as obesity could also have improved 
measurement on confounding. Finally, VE and rVE are 
likely to be impacted by the season-dependent match 
between the vaccine and the predominant circulating 
strain, as well as by the severity of the influenza sea-
son [13].
Conclusion
Using a combination of approaches, we estimated rVE 
and mortality in a predominantly male, white, senior 
VHA patient population. We found that HD was asso-
ciated with a lower risk of influenza/pneumonia-asso-
ciated and cardiorespiratory mortality during the high 
influenza period, an effect that could vary by season.
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